Navigation Links
Drug Proves Effective in Slowing Melanomas

Riluzole, used to treat Lou Gehrig's disease, inhibits aggressive growth, study finds

TUESDAY, April 15 (HealthDay News) -- The drug riluzole, approved in the United States to treat amyotrophic lateral sclerosis (ALS), slows the growth of highly aggressive melanoma skin cancer, according to a new study.

A common feature of both melanoma and ALS (also called Lou Gehrig's disease) is an excess amount of the protein glutamate, a cellular growth factor or food for cells. Too much glutamate can overstimulate neurons to the point where they burn out -- a possible explanation for what happens in ALS, according to background information in the study. Overproduction of glutamate causes the growth and expansion of melanoma.

Riluzole (brand name Rilutek) inhibits the release of glutamate.

In laboratory tests using cultures of human melanoma cell lines, researchers at Rutgers University and the Cancer Institute of New Jersey found that riluzole appeared to switch off overproduction of glutamate and slow the growth rate of the melanoma cells. In tests on animals, the drug showed the same suppression of melanoma cell growth.

The researchers then started testing the drug on 11 people with late-stage (stage 3 or 4) melanoma. The patients in this phase 0 (exploratory, first-in-humans) trial received riluzole for two weeks.

"Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date," Dr. James Goydos, a surgical oncologist at the Cancer Institute of New Jersey, said in a prepared statement.

Other patients in the group showed some indications of responding to the drug, and they'll be reassessed at the end of the trial.

The research was to be presented April 15 at the annual meeting of the American Association for Cancer Research, in San Diego.

The findings provide "enough data to show that we should go on to a more extensive (phase 1/2) trial," Goydos said. He expects it will begin later this year and include 50 to 100 patients with stage 4 melanoma.

"I think this drug is going to be extremely important as an adjunct to surgical treatment of stage 3 or stage 4 melanoma," Goydos said. "The challenge is to keep it from recurring, which has happened in patients on the order of 50 percent. With low toxicity likely, riluzole could potentially be given for long periods of time to slow down the metabolic process responsible for the disease's recurrence."

More information

The U.S. National Cancer Institute has more about melanoma.

-- Robert Preidt

SOURCE: Rutgers University, news release, April 15, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software ... , The new Q-Suite 6 platform is based on the latest Java Enterprise standards. ... specific piece of software for many key components of the suite. Much of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is jam-packed ... the palates of attendees is of the utmost importance. Whether you are cooking ... give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the ... several models of traditional and far-infrared saunas. , For traditional saunas, Finnleo ... most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology: